References for: association

Full identifier: http://purl.org/np/RAUN-q-5YeprGlPXyhTSB2oS4jgUSC7xCiKPz2x83073o#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Aripiprazole in the treatment of BPD: Highly inappropriate = 44 (21.8%); Innapropriate = 38 (18.8%); Doubt = 74 (36.6%); Appropriate = 43 (21.3%); Highly appropriate = 3 (1.5%)
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Aripiprazole in the treatment of BPD: Highly inappropriate = 44 (21.8%); Innapropriate = 38 (18.8%); Doubt = 74 (36.6%); Appropriate = 43 (21.3%); Highly appropriate = 3 (1.5%)
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-16T20:58:27.988Z